Categories: HealthcareNews

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.

Investor Conference Details:

A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com

Staff

Recent Posts

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in…

2 hours ago

Swell Launches Employee Experience Insights to Give Healthcare Organizations Real-Time Employee Feedback

HOLLADAY, UT / ACCESSWIRE / November 14, 2024 / Swell, a leader in feedback management…

2 hours ago

MDaudit’s 2024 Benchmark Report Reveals a Fivefold Increase in Dollars At-Risk from Payer Audits while Coding-Related Denials Surged by Over 125%

Amid skyrocketing audit and denial rates, slower reimbursements, and lower dollars paid per claim, continuous…

2 hours ago

Zane Networks Awarded Blanket Purchase Agreement for Health and Human Services’ Health IT Alignment Initiative

WASHINGTON, DC / ACCESSWIRE / November 14, 2024 / Zane Networks, LLC, a leader in…

2 hours ago

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

This post was written and published as a collaboration between the in-house editorial team at…

2 hours ago